* Opko Health CEO Phillip Frost reports purchase of 40,000 shares of co's common stock on Aug 16 - SEC filing Source text: (bit.ly/2i8raa9) Further company coverage:
How about three reasons, courtesy of Cantor analyst Louise Chen. Chen initiated coverage of Opko Health’s stock with a Buy rating and $20, which implies an …
These are 2 Hold Ratings, 6 Buy Ratings . The current consensus rating for Opko Health, Inc. (NASDAQ:OPK) is Buy (Score: 2.75) with a consensus target price of $16.43 , a potential (179.40% upside) Shares of Opko Health, Inc. …
Opko Health (NASDAQ: OPK) stock is down more than 30% so far in 2017. Its …
NWI1d
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here. Sportmans Warehouse (NASDAQ: SPWH) gained 15%; reported Q2 EPS of $0.15, $0.02 better than the analyst …
Opko released its Q2 2017 earnings report after the market closed on Tuesday. EPS beats by $.01 (-$0.04), and revenues misses by $8.44 million (-12.0% YOY). The stock is trading higher, here's why. Subscribers to ALR's Trading Ideas …
Bank of Montreal Can now owns 1,044,576 shares of the biotechnology company's stock worth $8,357,000 after buying an additional 14,559 shares during the last quarter. Following the completion of the transaction, the insider now owns …
OPKO Health, Inc.OPK reported loss of 4 cents per share in the ... primarily driven by strong sales growth at the company's transcatheter heart valves business. The stock has gained around 3.5% over the last three months. Steris …
Additionally, Xenetic has previously received strategic investments from OPKO